Achilles Therapeutics, a clinical-stage biopharmaceutical company, announced on April 12, 2022 that it is expanding its clinical manufacturing capabilities in the United Kingdom and the United States. The company’s manufacturing facility in Stevenage, UK, has received a manufacturing license from the UK Medicines and Healthcare products Regulatory Agency (MHRA), Following the receipt of the manufacturing license from the MHRA, the Stevenage facility is now GMP-certified to produce clinical-grade doses of cNeT, the company’s personalized clonal neoantigen-reactive T cell product candidates. This facility will have an annual capacity of 200 cNeT doses at peak production. Source: Biopharm International 14/4/22